{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:19:09Z","timestamp":1784989149725,"version":"3.55.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>All anthracyclines, including doxorubicin (DOXO), the most common and still indispensable drug, exhibit cardiotoxicity with inherent risk of irreversible cardiomyopathy leading to heart failure with reduced ejection fraction (HFrEF). Current pharmacological strategies are clearly less effective for this type of HFrEF, hence an urgent need for new therapeutic approaches. The prerequisite for success is thorough understanding of pathophysiology of this HFrEF form, which requires an appropriate animal model of the disease. The aim of this study was to comprehensively characterise a novel model of HF with cardiorenal syndrome, <jats:italic>i.e<\/jats:italic>. DOXO-induced HFrEF with nephrotic syndrome, in which DOXO was administered to Ren-2 transgenic rats (TGR) <jats:italic>via<\/jats:italic> five intravenous injections in a cumulative dose of 10\u2009mg\/kg of body weight (BW). Our analysis included survival, echocardiography, as well as histological examination of the heart and kidneys, blood pressure, but also a broad spectrum of biomarkers to evaluate cardiac remodelling, fibrosis, apoptosis, oxidative stress and more. We have shown that the new model adequately mimics the cardiac remodelling described as \u201ceccentric chamber atrophy\u201d and myocardial damage typical for DOXO-related cardiotoxicity, without major damage of the peritoneum, lungs and liver. This pattern corresponds well to a clinical situation of cancer patients receiving anthracyclines, where HF develops with some delay after the anticancer therapy. Therefore, this study may serve as a comprehensive reference for all types of research on DOXO-related cardiotoxicity, proving especially useful in the search for new therapeutic strategies.<\/jats:p>","DOI":"10.1038\/s41440-024-01865-7","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T03:09:21Z","timestamp":1725851361000},"page":"3126-3146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats"],"prefix":"10.1038","volume":"47","author":[{"given":"Olga","family":"Gawrys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160\u00e1rka","family":"J\u00edchov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00fa\u0161","family":"Miklovi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Huskov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So\u0148a","family":"Kikerlov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Koll\u00e1rov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Len\u010dov\u00e1-Popelova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Ho\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Imig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvona","family":"Mazurova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franti\u0161ek","family":"Kol\u00e1\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojt\u011bch","family":"Melenovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"\u0160t\u011brba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lud\u011bk","family":"\u010cervenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"1865_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","volume":"4","author":"T Omland","year":"2022","unstructured":"Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 2022;4:19\u201337.","journal-title":"JACC CardioOncol"},{"key":"1865_CR2","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.863314","volume":"9","author":"JT Vuong","year":"2022","unstructured":"Vuong JT, Stein-Merlob AF, Cheng RK, Yang EH. Novel therapeutics for anthracycline induced cardiotoxicity. Front Cardiovasc Med. 2022;9:863314.","journal-title":"Front Cardiovasc Med"},{"key":"1865_CR3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaccao.2020.08.006","volume":"2","author":"JM Leerink","year":"2020","unstructured":"Leerink JM, de Baat EC, Feijen EAM, Bellersen L, van Dalen EC, Grotenhuis HB, et al. Cardiac disease in childhood cancer survivors: risk prediction, prevention, and surveillance: JACC cardiooncology state-of-the-art review. JACC CardioOncol 2020;2:363\u201378.","journal-title":"JACC CardioOncol"},{"key":"1865_CR4","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869\u201379.","journal-title":"Cancer"},{"key":"1865_CR5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/cphy.c180017","volume":"9","author":"TR Mancilla","year":"2019","unstructured":"Mancilla TR, Iskra B, Aune GJ. Doxorubicin-induced cardiomyopathy in children. Compr Physiol. 2019;9:905\u201331.","journal-title":"Compr Physiol"},{"key":"1865_CR6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981\u20138.","journal-title":"Circulation"},{"key":"1865_CR7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1053\/j.ajkd.2012.08.048","volume":"61","author":"N Mohamed","year":"2013","unstructured":"Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis. 2013;61:778\u201381.","journal-title":"Am J Kidney Dis"},{"key":"1865_CR8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00011-015-0813-1","volume":"64","author":"F Pereira Wde","year":"2015","unstructured":"Pereira Wde F, Brito-Melo GE, de Almeida CA, Moreira LL, Cordeiro CW, Carvalho TG, et al. The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update. Inflamm Res. 2015;64:287\u2013301.","journal-title":"Inflamm Res"},{"key":"1865_CR9","doi-asserted-by":"crossref","first-page":"e0212486","DOI":"10.1371\/journal.pone.0212486","volume":"14","author":"MKO Grant","year":"2019","unstructured":"Grant MKO, Seelig DM, Sharkey LC, Choi WSV, Abdelgawad IY, Zordoky BN. Sexual dimorphism of acute doxorubicin-induced nephrotoxicity in C57Bl\/6 mice. PLoS One. 2019;14:e0212486.","journal-title":"PLoS One"},{"key":"1865_CR10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10555-020-09859-w","volume":"39","author":"N Bansal","year":"2020","unstructured":"Bansal N, Blanco JG, Sharma UC, Pokharel S, Shisler S, Lipshultz SE. Cardiovascular diseases in survivors of childhood cancer. Cancer Metastasis Rev. 2020;39:55\u201368.","journal-title":"Cancer Metastasis Rev"},{"key":"1865_CR11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113316","volume":"153","author":"S Kiaunyte","year":"2022","unstructured":"Kiaunyte S, Maske R, Kiudeliene R, Rutkauskiene G. Chemotherapy induced kidney and urinary tract related complications: A study in the Department of Pediatric Oncology and Hematology. Biomed Pharmacother. 2022;153:113316.","journal-title":"Biomed Pharmacother"},{"key":"1865_CR12","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/eurheartj\/ehy026","volume":"39","author":"J Faber","year":"2018","unstructured":"Faber J, Wingerter A, Neu MA, Henninger N, Eckerle S, Munzel T, et al. Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study. Eur Heart J. 2018;39:1555\u201362.","journal-title":"Eur Heart J"},{"key":"1865_CR13","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","volume":"355","author":"KC Oeffinger","year":"2006","unstructured":"Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl J Med. 2006;355:1572\u201382.","journal-title":"N. Engl J Med"},{"key":"1865_CR14","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(22)02471-0","volume":"401","author":"SB Dixon","year":"2023","unstructured":"Dixon SB, Liu Q, Chow EJ, Oeffinger KC, Nathan PC, Howell RM, et al. Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet. 2023;401:1447\u201357.","journal-title":"Lancet"},{"key":"1865_CR15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5306\/wjco.v11.i4.190","volume":"11","author":"MLC Santos","year":"2020","unstructured":"Santos MLC, de Brito BB, da Silva FAF, Botelho A, de Melo FF. Nephrotoxicity in cancer treatment: an overview. World J Clin Oncol. 2020;11:190\u2013204.","journal-title":"World J Clin Oncol"},{"key":"1865_CR16","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/ejhf.2149","volume":"23","author":"M Packer","year":"2021","unstructured":"Packer M, McMurray JJV. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur J Heart Fail. 2021;23:882\u201394.","journal-title":"Eur J Heart Fail"},{"key":"1865_CR17","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"1865_CR18","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895\u20131032.","journal-title":"Circulation"},{"key":"1865_CR19","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement From the American Heart Association. Circulation. 2019;139:e840\u201378.","journal-title":"Circulation"},{"key":"1865_CR20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1161\/CIRCRESAHA.122.321368","volume":"130","author":"A Rosenzweig","year":"2022","unstructured":"Rosenzweig A. The growing importance of basic models of cardiovascular disease. Circ Res. 2022;130:1743\u20136.","journal-title":"Circ Res"},{"key":"1865_CR21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd4051","volume":"12","author":"RM Plenge","year":"2013","unstructured":"Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12:581\u201394.","journal-title":"Nat Rev Drug Discov"},{"key":"1865_CR22","first-page":"e21","volume":"129","author":"A Asnani","year":"2021","unstructured":"Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, de Boer RA, et al. Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the American Heart Association. Circ Res. 2021;129:e21\u201334.","journal-title":"Circ Res"},{"key":"1865_CR23","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/cvr\/cvz161","volume":"115","author":"C Riehle","year":"2019","unstructured":"Riehle C, Bauersachs J. Small animal models of heart failure. Cardiovasc Res. 2019;115:1838\u201349.","journal-title":"Cardiovasc Res"},{"key":"1865_CR24","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1161\/CIRCRESAHA.122.320246","volume":"130","author":"PM Pilz","year":"2022","unstructured":"Pilz PM, Ward JE, Chang WT, Kiss A, Bateh E, Jha A, et al. Large and small animal models of heart failure with reduced ejection fraction. Circ Res. 2022;130:1888\u2013905.","journal-title":"Circ Res"},{"key":"1865_CR25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/CS20210836","volume":"136","author":"Z Pokorna","year":"2022","unstructured":"Pokorna Z, Kollarova-Brazdova P, Lencova-Popelova O, Jirkovsky E, Kubes J, Mazurova Y, et al. Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up. Clin Sci (Lond). 2022;136:139\u201361.","journal-title":"Clin Sci (Lond)"},{"key":"1865_CR26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12012-022-09721-1","volume":"22","author":"M Sheibani","year":"2022","unstructured":"Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, et al. Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol. 2022;22:292\u2013310.","journal-title":"Cardiovasc Toxicol"},{"key":"1865_CR27","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s12012-021-09694-7","volume":"21","author":"MMM Refaie","year":"2021","unstructured":"Refaie MMM, Shehata S, Ibrahim RA, Bayoumi AMA, Abdel-Gaber SA. Dose-dependent cardioprotective effect of hemin in doxorubicin-induced cardiotoxicity via Nrf-2\/HO-1 and TLR-5\/NF-kappaB\/TNF-alpha signaling pathways. Cardiovasc Toxicol. 2021;21:1033\u201344.","journal-title":"Cardiovasc Toxicol"},{"key":"1865_CR28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/0895-7061(95)00400-9","volume":"9","author":"M Langheinrich","year":"1996","unstructured":"Langheinrich M, Lee MA, Bohm M, Pinto YM, Ganten D, Paul M. The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens. 1996;9:506\u201312.","journal-title":"Am J Hypertens"},{"key":"1865_CR29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.120.048655","volume":"142","author":"J Moslehi","year":"2020","unstructured":"Moslehi J, Zhang Q, Moore KJ. Crosstalk between the heart and cancer: beyond drug toxicity. Circulation. 2020;142:684\u20137.","journal-title":"Circulation"},{"key":"1865_CR30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","volume":"19","author":"JL Zamorano","year":"2017","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19:9\u201342.","journal-title":"Eur J Heart Fail"},{"key":"1865_CR31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.hfc.2019.06.010","volume":"15","author":"LJ Hassen","year":"2019","unstructured":"Hassen LJ, Lenihan DJ, Baliga RR. Hypertension in the cardio-oncology clinic. Heart Fail Clin. 2019;15:487\u201395.","journal-title":"Heart Fail Clin"},{"key":"1865_CR32","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101394","volume":"29","author":"B Kalyanaraman","year":"2020","unstructured":"Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biol. 2020;29:101394.","journal-title":"Redox Biol"},{"key":"1865_CR33","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.742193","volume":"9","author":"K Agostinucci","year":"2022","unstructured":"Agostinucci K, Grant MKO, Seelig D, Yucel D, van Berlo J, Bartolomucci A, et al. Divergent cardiac effects of angiotensin ii and isoproterenol following juvenile exposure to doxorubicin. Front Cardiovasc Med. 2022;9:742193.","journal-title":"Front Cardiovasc Med"},{"key":"1865_CR34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","volume":"27","author":"P Sobczuk","year":"2022","unstructured":"Sobczuk P, Czerwinska M, Kleibert M, Cudnoch-Jedrzejewska A. Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart Fail Rev. 2022;27:295\u2013319.","journal-title":"Heart Fail Rev"},{"key":"1865_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21249337","volume":"21","author":"P Kala","year":"2020","unstructured":"Kala P, Bartuskova H, Pitha J, Vanourkova Z, Kikerlova S, Jichova S, et al. Deleterious effects of hyperactivity of the renin-angiotensin system and hypertension on the course of chemotherapy-induced heart failure after doxorubicin administration: a study in Ren-2 transgenic rat. Int J Mol Sci. 2020;21:1\u201320.","journal-title":"Int J Mol Sci"},{"key":"1865_CR36","doi-asserted-by":"crossref","first-page":"8475","DOI":"10.3390\/ijms22168475","volume":"22","author":"S Jichova","year":"2021","unstructured":"Jichova S, Gawrys O, Kompanowska-Jezierska E, Sadowski J, Melenovsky V, Hoskova L, et al. Kidney response to chemotherapy-induced heart failure: mRNA analysis in normotensive and ren-2 transgenic hypertensive rats. Int J Mol Sci. 2021;22:8475.","journal-title":"Int J Mol Sci"},{"key":"1865_CR37","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1139\/y87-305","volume":"65","author":"LE Weinberg","year":"1987","unstructured":"Weinberg LE, Singal PK. Refractory heart failure and age-related differences in adriamycin-induced myocardial changes in rats. Can J Physiol Pharm. 1987;65:1957\u201365.","journal-title":"Can J Physiol Pharm"},{"key":"1865_CR38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-4939-8597-5_17","volume":"1816","author":"T Nakahara","year":"2018","unstructured":"Nakahara T, Tanimoto T, Petrov AD, Ishikawa K, Strauss HW, Narula J. Rat model of cardiotoxic drug-induced cardiomyopathy. Methods Mol Biol. 2018;1816:221\u201332.","journal-title":"Methods Mol Biol"},{"key":"1865_CR39","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008209","volume":"14","author":"E Jirkovsky","year":"2021","unstructured":"Jirkovsky E, Jirkovska A, Bavlovic-Piskackova H, Skalicka V, Pokorna Z, Karabanovich G, et al. Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II beta and not metal chelation. Circ Heart Fail. 2021;14:e008209.","journal-title":"Circ Heart Fail"},{"key":"1865_CR40","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1042\/CS20210311","volume":"135","author":"P Kollarova-Brazdova","year":"2021","unstructured":"Kollarova-Brazdova P, Lencova-Popelova O, Karabanovich G, Kocurova-Lengvarska J, Kubes J, Vanova N, et al. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo. Clin Sci (Lond). 2021;135:1897\u2013914.","journal-title":"Clin Sci (Lond)"},{"key":"1865_CR41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCHEARTFAILURE.114.001180","volume":"8","author":"M Moulin","year":"2015","unstructured":"Moulin M, Piquereau J, Mateo P, Fortin D, Rucker-Martin C, Gressette M, et al. Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling. Circ Heart Fail. 2015;8:98\u2013108.","journal-title":"Circ Heart Fail"},{"key":"1865_CR42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.hjh.0000917496.33970.53","volume":"41","author":"P Kala","year":"2023","unstructured":"Kala P, Gawrys O, Miklovic M, Vanourkova Z, Skaroupkova P, Jichova S, et al. Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension. J Hypertens. 2023;41:99\u2013114.","journal-title":"J Hypertens"},{"key":"1865_CR43","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/biomedicines9081053","volume":"9","author":"P Kala","year":"2021","unstructured":"Kala P, Miklovic M, Jichova S, Skaroupkova P, Vanourkova Z, Maxova H, et al. Effects of epoxyeicosatrienoic acid-enhancing therapy on the course of congestive heart failure in angiotensin II-dependent rat hypertension: from mRNA analysis towards functional in vivo evaluation. Biomedicines. 2021;9:1053.","journal-title":"Biomedicines"},{"key":"1865_CR44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/1440-1681.12553","volume":"43","author":"Z Huskova","year":"2016","unstructured":"Huskova Z, Kopkan L, Cervenkova L, Dolezelova S, Vanourkova Z, Skaroupkova P, et al. Intrarenal alterations of the angiotensin-converting enzyme type 2\/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharm Physiol. 2016;43:438\u201349.","journal-title":"Clin Exp Pharm Physiol"},{"key":"1865_CR45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/1440-1681.12310","volume":"41","author":"A Sporkova","year":"2014","unstructured":"Sporkova A, Jichova S, Huskova Z, Kopkan L, Nishiyama A, Hwang SH, et al. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharm Physiol. 2014;41:1003\u201313.","journal-title":"Clin Exp Pharm Physiol"},{"key":"1865_CR46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/01.hjh.0000209988.51606.c7","volume":"24","author":"Z Huskova","year":"2006","unstructured":"Huskova Z, Kramer HJ, Vanourkova Z, Cervenka L. Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J Hypertens. 2006;24:517\u201327.","journal-title":"J Hypertens"},{"key":"1865_CR47","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/1440-1681.12419","volume":"42","author":"L Cervenka","year":"2015","unstructured":"Cervenka L, Melenovsky V, Huskova Z, Skaroupkova P, Nishiyama A, Sadowski J. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula. Clin Exp Pharm Physiol. 2015;42:795\u2013807.","journal-title":"Clin Exp Pharm Physiol"},{"key":"1865_CR48","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1159\/000495391","volume":"43","author":"V Kratky","year":"2018","unstructured":"Kratky V, Kopkan L, Kikerlova S, Huskova Z, Taborsky M, Sadowski J, et al. The role of renal vascular reactivity in the development of renal dysfunction in compensated and decompensated congestive heart failure. Kidney Blood Press Res. 2018;43:1730\u201341.","journal-title":"Kidney Blood Press Res"},{"key":"1865_CR49","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/HJH.0000000000002462","volume":"38","author":"O Gawrys","year":"2020","unstructured":"Gawrys O, Huskova Z, Baranowska I, Walkowska A, Sadowski J, Kikerlova S, et al. Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. J Hypertens. 2020;38:1802\u201310.","journal-title":"J Hypertens"},{"key":"1865_CR50","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1440-1827.2008.02237.x","volume":"58","author":"Y Nakano","year":"2008","unstructured":"Nakano Y, Hirano T, Uehara K, Nishibayashi S, Hattori K, Aihara M, et al. New rat model induced by anti-glomerular basement membrane antibody shows severe glomerular adhesion in early stage and quickly progresses to end-stage renal failure. Pathol Int. 2008;58:361\u201370.","journal-title":"Pathol Int"},{"key":"1865_CR51","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/10641963.2016.1182182","volume":"38","author":"S Dolezelova","year":"2016","unstructured":"Dolezelova S, Jichova S, Huskova Z, Vojtiskova A, Kujal P, Hoskova L, et al. Progression of hypertension and kidney disease in aging fawn-hooded rats is mediated by enhanced influence of renin-angiotensin system and suppression of nitric oxide system and epoxyeicosanoids. Clin Exp Hypertens. 2016;38:644\u201351.","journal-title":"Clin Exp Hypertens"},{"key":"1865_CR52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fphar.2019.00018","volume":"10","author":"S Vackova","year":"2019","unstructured":"Vackova S, Kopkan L, Kikerlova S, Huskova Z, Sadowski J, Kompanowska-Jezierska E, et al. Pharmacological blockade of soluble epoxide hydrolase attenuates the progression of congestive heart failure combined with chronic kidney disease: insights from studies with fawn-hooded hypertensive rats. Front Pharm. 2019;10:18.","journal-title":"Front Pharm"},{"key":"1865_CR53","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/10641963.2021.1907398","volume":"43","author":"Z Honetschlagerova","year":"2021","unstructured":"Honetschlagerova Z, Skaroupkova P, Kikerlova S, Huskova Z, Maxova H, Melenovsky V, et al. Effects of renal sympathetic denervation on the course of congestive heart failure combined with chronic kidney disease: Insight from studies with fawn-hooded hypertensive rats with volume overload induced using aorto-caval fistula. Clin Exp Hypertens. 2021;43:522\u201335.","journal-title":"Clin Exp Hypertens"},{"key":"1865_CR54","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114157","volume":"158","author":"P Kala","year":"2023","unstructured":"Kala P, Vanourkova Z, Skaroupkova P, Kompanowska-Jezierska E, Sadowski J, Walkowska A, et al. Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: Studies in 5\/6 nephrectomized rats with aorto-caval fistula. Biomed Pharmacother. 2023;158:114157.","journal-title":"Biomed Pharmacother"},{"key":"1865_CR55","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1007\/s00210-023-02561-y","volume":"396","author":"O Gawrys","year":"2023","unstructured":"Gawrys O, Huskova Z, Skaroupkova P, Honetschlagerova Z, Vanourkova Z, Kikerlova S, et al. The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula. Naunyn Schmiedebergs Arch Pharm. 2023;396:3757\u201373.","journal-title":"Naunyn Schmiedebergs Arch Pharm"},{"key":"1865_CR56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coph.2017.03.005","volume":"33","author":"D Peana","year":"2017","unstructured":"Peana D, Domeier TL. Cardiomyocyte Ca(2+) homeostasis as a therapeutic target in heart failure with reduced and preserved ejection fraction. Curr Opin Pharm. 2017;33:17\u201326.","journal-title":"Curr Opin Pharm"},{"key":"1865_CR57","first-page":"81","volume":"279","author":"D Tsikas","year":"2004","unstructured":"Tsikas D. Measurement of nitric oxide synthase activity in vivo and in vitro by gas chromatography-mass spectrometry. Methods Mol Biol. 2004;279:81\u2013103.","journal-title":"Methods Mol Biol"},{"key":"1865_CR58","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/10715760500053651","volume":"39","author":"D Tsikas","year":"2005","unstructured":"Tsikas D. Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids. Free Radic Res. 2005;39:797\u2013815.","journal-title":"Free Radic Res"},{"key":"1865_CR59","first-page":"195","volume":"58","author":"EH Herman","year":"1998","unstructured":"Herman EH, Lipshultz SE, Rifai N, Zhang J, Papoian T, Yu ZX, et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 1998;58:195\u20137.","journal-title":"Cancer Res"},{"key":"1865_CR60","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s004320050273","volume":"125","author":"M Adamcova","year":"1999","unstructured":"Adamcova M, Gersl V, Hrdina R, Melka M, Mazurova Y, Vavrova J, et al. Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol. 1999;125:268\u201374.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1865_CR61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0009-8981(03)00013-5","volume":"329","author":"JP Bertinchant","year":"2003","unstructured":"Bertinchant JP, Polge A, Juan JM, Oliva-Lauraire MC, Giuliani I, Marty-Double C, et al. Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta. 2003;329:39\u201351.","journal-title":"Clin Chim Acta"},{"key":"1865_CR62","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708.","journal-title":"Biomed Pharmacother"},{"key":"1865_CR63","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jjcc.2022.01.001","volume":"80","author":"K Shinlapawittayatorn","year":"2022","unstructured":"Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N. The effects of doxorubicin on cardiac calcium homeostasis and contractile function. J Cardiol. 2022;80:125\u201332.","journal-title":"J Cardiol"},{"key":"1865_CR64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.repbio.2019.02.004","volume":"19","author":"K Renu","year":"2019","unstructured":"Renu K, Valsala Gopalakrishnan A. Deciphering the molecular mechanism during doxorubicin-mediated oxidative stress, apoptosis through Nrf2 and PGC-1alpha in a rat testicular milieu. Reprod Biol. 2019;19:22\u201337.","journal-title":"Reprod Biol"},{"key":"1865_CR65","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1749-6632.2010.05612.x","volume":"1201","author":"AK Holley","year":"2010","unstructured":"Holley AK, Dhar SK, St, Clair DK. Manganese superoxide dismutase versus p53: the mitochondrial center. Ann N. Y Acad Sci. 2010;1201:72\u20138.","journal-title":"Ann N. Y Acad Sci"},{"key":"1865_CR66","doi-asserted-by":"crossref","first-page":"e96055","DOI":"10.1371\/journal.pone.0096055","volume":"9","author":"O Lencova-Popelova","year":"2014","unstructured":"Lencova-Popelova O, Jirkovsky E, Mazurova Y, Lenco J, Adamcova M, Simunek T, et al. Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. PLoS One. 2014;9:e96055.","journal-title":"PLoS One"},{"key":"1865_CR67","first-page":"13","volume":"99","author":"JF Vanvleet","year":"1980","unstructured":"Vanvleet JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin-E and selenium as cardioprotectants. Am J Pathol. 1980;99:13\u201341.","journal-title":"Am J Pathol"},{"key":"1865_CR68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1015976430790","volume":"234-235","author":"B Kalyanaraman","year":"2002","unstructured":"Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem. 2002;234-235:119\u201324.","journal-title":"Mol Cell Biochem"},{"key":"1865_CR69","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/clc.22672","volume":"40","author":"M Tadic","year":"2017","unstructured":"Tadic M, Cuspidi C, Hering D, Venneri L, Danylenko O. The influence of chemotherapy on the right ventricle: did we forget something? Clin Cardiol. 2017;40:437\u201343.","journal-title":"Clin Cardiol"},{"key":"1865_CR70","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.biopha.2017.12.051","volume":"98","author":"B Sutariya","year":"2018","unstructured":"Sutariya B, Saraf M. alpha-asarone reduce proteinuria by restoring antioxidant enzymes activities and regulating necrosis factor kappaB signaling pathway in doxorubicin-induced nephrotic syndrome. Biomed Pharmacother. 2018;98:318\u201324.","journal-title":"Biomed Pharmacother"},{"key":"1865_CR71","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1046\/j.1523-1755.2000.00342.x","volume":"58","author":"Y Wang","year":"2000","unstructured":"Wang Y, Wang YP, Tay YC, Harris DC. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 2000;58:1797\u2013804.","journal-title":"Kidney Int"},{"key":"1865_CR72","first-page":"16","volume":"46","author":"T Bertani","year":"1982","unstructured":"Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest. 1982;46:16\u201323.","journal-title":"Lab Invest"},{"key":"1865_CR73","first-page":"479","volume":"93","author":"C Kodner","year":"2016","unstructured":"Kodner C. Diagnosis and management of nephrotic syndrome in adults. Am Fam Physician. 2016;93:479\u201385.","journal-title":"Am Fam Physician"},{"key":"1865_CR74","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00018-020-03729-y","volume":"78","author":"AJ Wang","year":"2021","unstructured":"Wang AJ, Zhang J, Xiao M, Wang S, Wang BJ, Guo Y, et al. Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways. Cell Mol Life Sci. 2021;78:3105\u201325.","journal-title":"Cell Mol Life Sci"},{"key":"1865_CR75","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/15376516.2012.759306","volume":"23","author":"S Rashid","year":"2013","unstructured":"Rashid S, Ali N, Nafees S, Ahmad ST, Arjumand W, Hasan SK, et al. Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicol Mech Methods. 2013;23:337\u201345.","journal-title":"Toxicol Mech Methods"},{"key":"1865_CR76","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2174\/138945012802002348","volume":"13","author":"PR Evora","year":"2012","unstructured":"Evora PR, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. Curr Drug Targets. 2012;13:1207\u201314.","journal-title":"Curr Drug Targets"},{"key":"1865_CR77","doi-asserted-by":"publisher","unstructured":"Sandner P, Follmann M, Becker-Pelster E, Hahn MG, Meier C, Freitas C, et al. Soluble GC stimulators and activators: Past, present and future. Br J Pharmacol. 2021;1\u201322. https:\/\/doi.org\/10.1111\/bph.15698.","DOI":"10.1111\/bph.15698"},{"key":"1865_CR78","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/HYPERTENSIONAHA.120.15856","volume":"76","author":"E Ataei Ataabadi","year":"2020","unstructured":"Ataei Ataabadi E, Golshiri K, Juttner A, Krenning G, Danser AHJ, Roks AJM. Nitric oxide-cGMP signaling in hypertension: current and future options for pharmacotherapy. Hypertension. 2020;76:1055\u201368.","journal-title":"Hypertension"},{"key":"1865_CR79","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3390\/ijms19061712","volume":"19","author":"SM Krishnan","year":"2018","unstructured":"Krishnan SM, Kraehling JR, Eitner F, Benardeau A, Sandner P. The impact of the nitric oxide (NO)\/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective. Int J Mol Sci. 2018;19:1712.","journal-title":"Int J Mol Sci"},{"key":"1865_CR80","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883\u201393.","journal-title":"N Engl J Med"},{"key":"1865_CR81","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13543776.2021.1866538","volume":"31","author":"P Sandner","year":"2021","unstructured":"Sandner P, Vakalopoulos A, Hahn MG, Stasch JP, Follmann M. Soluble guanylate cyclase stimulators and their potential use: a patent review. Expert Opin Ther Pat. 2021;31:203\u201322.","journal-title":"Expert Opin Ther Pat"},{"key":"1865_CR82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/bi4015133","volume":"53","author":"R Purohit","year":"2014","unstructured":"Purohit R, Fritz BG, The J, Issaian A, Weichsel A, David CL, et al. YC-1 binding to the beta subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the alpha subunit. Biochemistry. 2014;53:101\u201314.","journal-title":"Biochemistry"},{"key":"1865_CR83","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ehjcvp\/pvab030","volume":"7","author":"R Pontremoli","year":"2021","unstructured":"Pontremoli R, Borghi C, Perrone Filardi P. Renal protection in chronic heart failure: focus on sacubitril\/valsartan. Eur Heart J Cardiovasc Pharmacother. 2021;7:445\u201352.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1865_CR84","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40256-021-00487-5","volume":"22","author":"H Cho","year":"2022","unstructured":"Cho H, Zhao XX, Lee S, Woo JS, Song MY, Cheng XW, et al. The sGC-cGMP signaling pathway as a potential therapeutic target in doxorubicin-induced heart failure: a narrative review. Am J Cardiovasc Drugs. 2022;22:117\u201325.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1865_CR85","first-page":"624","volume":"4","author":"P Sengupta","year":"2013","unstructured":"Sengupta P. The laboratory rat: relating its age with human\u2019s. Int J Prev Med. 2013;4:624\u201330.","journal-title":"Int J Prev Med"},{"key":"1865_CR86","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fneur.2017.00092","volume":"8","author":"DV Agoston","year":"2017","unstructured":"Agoston DV. How to translate time? the temporal aspect of human and rodent biology. Front Neurol. 2017;8:92.","journal-title":"Front Neurol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01865-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01865-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01865-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:05:35Z","timestamp":1730765135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01865-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1038\/s41440-024-01865-7","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}